Amphotericin B
Total Payments
$56,609
Transactions
2
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $56,609 | 2 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $56,609 | 2 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Fungal infections among lung transplant recipients despite voriconazole prophylaxis | Astellas Pharma Global Development | $29,609 | 0 |
| Fungal Infections Post-Influenza among Lung Transplant Recipients | Astellas Pharma Global Development | $27,000 | 0 |
Top Doctors Receiving Payments for Amphotericin B
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Pittsburgh, PA | $56,609 | 2 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $56,609
- Total Doctors 0
- Transactions 2
About Amphotericin B
Amphotericin B is a drug associated with $56,609 in payments to 0 healthcare providers, recorded across 2 transactions in the CMS Open Payments database. The primary manufacturer is Astellas Pharma Global Development.
Payment data is available from 2017 to 2017. In 2017, $56,609 was paid across 2 transactions to 0 doctors.
The most common payment nature for Amphotericin B is "Unspecified" ($56,609, 100.0% of total).
Amphotericin B is associated with 2 research studies, including "Fungal infections among lung transplant recipients despite voriconazole prophylaxis" ($29,609).